AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05067205 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Carpal tunnel release surgery
Description: Preoperative, 3 days, 2 weeks, 4 weeks and 24 weeks postoperatively
Study NCT04963283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib is a multi-targeted inhibitor of RTKs. The targets of cabozantinib include several RTKs known to play important roles in tumor cell proliferation and/or tumor neovascularization, namely MET, VEGFR2 (also known as KDR), AXL, and RET. Other recognized targets of cabozantinib include ROS1, TRKA, TRKB, TIE2, TYRO3, and MER, two additional members of the VEGFR family (VEGFR1, VEGFR3), and the closely related RTKs KIT and FLT-3. The mode of action for cabozantinib is similar to other drugs targeting RTKs: binding in a fully reversible manner to a region of the kinase domain (including the ATP-binding site) which forces the kinase activation loop into a pseudo-inactive conformation, thereby inhibiting subsequent catalytic activity.
Study NCT04963283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed death ligands-1 (PD-L1) and 2 (PD-L2), which promotes immune responses and antigen-specific T-cell responses to foreign- and self- antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies.
Study NCT05856071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: goniometer
Description: to measure the range of motion
Study NCT05856071 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: goniometer
Description: to measure the range of motion
Study NCT05856071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clamshells exercises
Description: clamshells exercises
Study NCT05856071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physical therapy
Description: traditional physical therapy
Study NCT05025410 — intervention group
Intervention type: DRUG
Intervention: Remimazolam
Description: Loading for anesthesia induction: Remimazolam 6 mg/kg/h until loss of consciousness Continuous infusion for anesthesia maintenance: Remimazolam 1-2 mg/kg/h under the Bispectral index monitoring
Study NCT04973995 — intervention group
Intervention type: BEHAVIORAL
Intervention: several physical examinations
Description: By using physical examinations, the incidence of these physical examinations corresponding to shoulder muscls injury
Study NCT04694118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rebound therapy
Description: 3 days a week in 12 weeks
Study NCT05438810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-437c,Fulvestrant,Goserelin acetate
Description: FCN-437c：available in 25mg and 100mg capsules for oral administration on an empty stomach. 200mg once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment until progressive disease。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles ； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
Study NCT05438810 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo,Fulvestrant,Goserelin acetate
Description: Placebo：available in 25mg and 100mg capsules, and is administered in the same way as FCN-437c。 Fulvestrant：500mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 only for other cycles； Goserelin acetate：premenopausal /perimenopausal patients should be coadministered with 3.6mg, Subcutaneously at every 28 days until progressive disease。
Study NCT02437552 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ergometer cycle exercise
Study NCT02437552 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: routine physiotherapy
Description: routine physiotherapy
Study NCT02437552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine physiotherapy
Description: routine physiotherapy
Study NCT04920539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Delta-9-THC
Description: Active Delta-9-THC (0.03 mg/kg) administered intravenously.
Study NCT04995900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community education
Description: Heart Matters coordinators will deliver heart health education to the community using HM materials and Partner resources.
Study NCT04403854 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: If possible with spectroscopy
Study NCT04403854 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal Tap
Description: together with CSF pressure estimate
Study NCT05177172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High beta glucans
Description: higher dose betaglucans
Study NCT05177172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low beta glucans
Description: lower dose beta glucans
Study NCT05177172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low beta glucans + low polar lipids
Description: low dose betaglucans in a combination with low dose of polar lipids
Study NCT05177172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polar lipids
Description: low dose polar lipids
Study NCT05177172 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: No beta glucans or polar lipids
Study NCT05035342 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT) capsules
Description: Donated fecal matter will be sequentially diluted in 80% glycerol used as bacterial cryoprotectant, blenderized, sieved and centrifuged (4°C, 4000 tr/min, 20 min). The pellet is resuspended and manually pipetted into size 0 capsules (650 μL), which are closed and then secondarily sealed in size 00 capsules (hypromellose capsules, DR caps from Capsugel®, MA). Each capsule contains 1g ± 0,1g of fecal suspension corresponding to 0.5 to 0.8g of native stool. Capsules will be stored frozen at -80°C for up to 24 months pending use. The stability of biodiversity and viability of the frozen microbiota was regularly verified to ensure the efficacy of the transplantation (personal data).
Study NCT05035342 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: The placebo FMT capsules will be performed with the final dilution solution, ie the 80% glycerol solution used as a cryoprotectant. This solution will be double encapsulated like the FMT capsules.
Study NCT05534737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAICP + usual care of social services
Description: The intervention consists of applying a MAICP from the municipal social services involved for 2 years (summer 2022-summer 2024). To this end, the AICP.com project will sign the necessary institutional agreements to contract and integrate, in the municipal Social Services of each territory, an intervention team that will work with them in a coordinated manner, although its specific task is the implementation of the MAICP during the intervention period of the project and the baseline, intermediate and final evaluations of the effectiveness of this model in the study population.
Study NCT06498115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Participants in this arm will receive norepinephrine as a bolus dose to treat maternal hypotension during cesarean section under spinal anesthesia. The dosage will be determined using the upper and lower sequential distribution method (UDM). The aim is to investigate the effective dose (ED50 and ED95) of norepinephrine in maintaining maternal blood pressure stability and optimizing maternal outcomes during the procedure.
Study NCT04891913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007/ Placebo 15mg
Description: 15 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
Study NCT04891913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007/ Placebo 30mg
Description: 30 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
Study NCT04891913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-007/ Placebo 60mg
Description: 60 mg SY-007/ Placebo, the dosing interval is 12 hours ±2 hours for 7 consecutive days.
Study NCT05186935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injectable Hydrogel treatment
Description: The Injectable Hydrogel is a single use two-component injectable and bioresorbable hydrogel intended for treatment of cartilage defects in the knee, it is a medical device, exclusively for clinical investigations. The hydrogel is mixed intraoperatively and with an open knee procedure inserted into the cartilage defect, where it crosslinks and adheres to the cartilage with the use of a primer, allowing it to stay in place during movements of the knee. The hydrogel covers the defect to prevent formation of scar tissue and to allow cartilage to regenerate. The Injectable Hydrogel will be used in combination with general instruments typically used. The different components of the Injectable Hydrogel are arranged in two boxes: Components of the Injectable Hydrogel are grouped in plastic cover bags or packaged in vial boxes.This is a performance study, with a single arm, i.e Injectable Hydrogel. Recovery is monitored.
Study NCT06079034 — intervention group
Intervention type: PROCEDURE
Intervention: Venovenous ECMO
Description: Initial support type of venovenous ECMO via a dual-lumen on two-site VV ECMO cannulation strategy
Study NCT06079034 — intervention group
Intervention type: PROCEDURE
Intervention: Venoarterial ECMO
Description: Initial support type of venoarterial ECMO
Study NCT06418685 — intervention group
Intervention type: DEVICE
Intervention: Treatment with Vibrating Capsule
Description: Main parameters of Vibrabot capsule: nominal diameter: 11.8±1mm; nominal length: 26.7±1mm; nominal weight: 4.5±1g.~After the patient swallows the Vibrabot capsule, the capsule runs through the stomach → duodenum → jejunum and ileum → colon. According to the clinical data and configuration settings, the capsule will reach the colon and vibrate 8 hours after activation for ≥ 180 minutes in a cycle at low, medium, and high frequencies sequentially. The capsule relieves and treats constipation by massaging the colon wall through motor vibration to relieve colon muscle spasms and promote colonic peristalsis.~The VC well be taken between 21:00 and 22:00 every day, and the frequency of administration is determined based on the patient's individual situation.
Study NCT05518084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liponovo tissue product
Description: Investigational products (Liponovo tissue product and Ringer Acetat) are injected into the dorsal forearm, superficial part of the subcutis. The single injection and a 23G/30mm needle are used. The amount of the injected investiogational products is 4,5 ml for both dorsal forearms (together 4,5ml x2 = 9ml / test subject). The product is always injected in the proximal third of the forearm, into a standardized a quarter circle with a radius of 30mm. Both injections are performed with covered syringe to ensure the double-blinding. After the injection, test subjects get a cold on the injection sites to reduce the bruising.
Study NCT05518084 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Liponovo tissue product
Description: Investigational products (Liponovo tissue product and Ringer Acetat) are injected into the dorsal forearm, superficial part of the subcutis. The single injection and a 23G/30mm needle are used. The amount of the injected investiogational products is 4,5 ml for both dorsal forearms (together 4,5ml x2 = 9ml / test subject). The product is always injected in the proximal third of the forearm, into a standardized a quarter circle with a radius of 30mm. Both injections are performed with covered syringe to ensure the double-blinding. After the injection, test subjects get a cold on the injection sites to reduce the bruising.
Study NCT00107549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])
Description: Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4
Study NCT00107549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])
Description: Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24
Study NCT04969718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEADS Plus educational posters
Description: This intervention covers depression and its symptoms, the link between depression and suicide, the risk and protective factors associated with suicide, the warning signs of suicide, seeking help and overcoming barriers to seeking help, and school and community suicide prevention resources. Six educational posters will also be displayed in class rooms
Study NCT04969718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Question, Persuade, and Refer (Teachers) Plus educational posters
Description: It is a manualised programme for gatekeepers, originally developed in the USA which to train teachers/school staff to identify the suicide risk in students and encourage students at risk of suicide to seek professional help. Six educational posters will also be displayed in classrooms.
Study NCT04969718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening by Professionals programme plus educational posters
Description: This is an indicated or selective intervention which is based on students' responses to the baseline questionnaires. Participating health professionals review students' responses to the questionnaires used in the study and students whose scores meet pre-established cutoff points will be invited to participate in a professional mental health clinical assessment and if needed, referred to clinical services. Six educational posters will also be displayed in classrooms.
Study NCT04969718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational posters
Description: Six educational posters will be displayed in all schools in this cluster.
Study NCT04969718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational posters
Description: Six educational posters will be displayed in all schools in this cluster.
Study NCT04969718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Question, Persuade, and Refer (Parents) Plus educational posters
Description: It is a manualised programme for gatekeepers (parents), originally developed in the USA which to train parents to support the young people at risk of suicide. Six educational posters will also be displayed in classrooms.
Study NCT06250049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetic foot care protocol
Description: Introduction of the diabetic foot care protocol in Primary Care in Salamanca, sensitization, and training of nursing professionals in Health Centers (HC).
Study NCT06250049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group education sessions for patients and/or caregivers
Description: Conducting group education sessions for patients and/or caregivers on Diabetic Foot Care at the Health Centers.
Study NCT05389683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elimination Diet
Description: An 'elimination diet' devoid of the reaction-inducing foods will be suggested for 4 weeks.
Study NCT05534737 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: usual care of social services
Study NCT05807399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ-043
Description: BTZ-043 1,000mg once daily.
Study NCT05807399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3.
Study NCT05807399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: Rifampicin will be dosed in a fixed high-dose (2100 mg for arms 1 and 2) or a weight-banded regular dose (10 mg/kg) in arm 3.
Study NCT05807399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3.
Study NCT05807399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid will be dosed at fixed dose of 300mg in arms 1 and 2, and regular dose of 5 mg/kg in arm 3.
Study NCT05897385 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine
Description: Intraperitoneal lignocaine 200mg/20mls + epinephrine 1:200,000
Study NCT06384820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cemiplimab
Description: Administered Intravenous (IV) infusion every three weeks (Q3W)
Study NCT06384820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fianlimab
Description: IV infusion Q3W
Study NCT05897385 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intraperitoneal 20ml of 0.9% normal saline
Study NCT04990596 — intervention group
Intervention type: BIOLOGICAL
Intervention: additional blood sample
Description: One sample per patient will be taken 1 to 3 hours after clopidogrel administration. Four additional tubes of 3 mL each will be collected for the study, for a total volume of 12 mL.
Study NCT05807399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3.
Study NCT05807399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: Pyrazinamide will be dosed in a fixed regular dose in arm 1 (1600 mg), a weight banded high dose in arm 2 (2000/2400 mg) or a weight-banded regular dose (25 mg/kg) in arm 3.
Study NCT05807399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin will be dosed at 600 mg orally once daily in arms 1-2:.
Study NCT05504590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tuohy needle group
Description: Ultrasound-guided caudal epidural block with Touhy needle
Study NCT05504590 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quincke needle group
Description: Ultrasound-guided caudal epidural block with Quincke needle
Study NCT06145568 — intervention group
Intervention type: OTHER
Intervention: Pregnant Women
Description: We want to quantify Minority Americans at risk of pregnancy complications
Study NCT05541341 — intervention group
Intervention type: OTHER
Intervention: tisagenlecleucel
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with tisagenlecleucel in the commercial setting or out-of-specification (OOS) are eligible to enroll into this study
Study NCT06499103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: The stimulation (TENS) will be performed by a physiotherapist using adhesive electrodes with an area of 5 cm2 in the region where the patient has the symptoms of neuropathy. Further, it will be will be on 10 days consequently, with the same physiotherapist for whole sessions. He will apply electrodes over the affected area, then he will increase the stimulation intensity gradually during the first session when he adjusts the settings till patient reach the maximum voltage that he/she will tolerate it. The evaluations for CIPN patients will be performed by a blinded evaluatorthe PI on the experimental groups at 3 time points; before the begging of the intervention, after 5 days, and after the last session. The intervention group will undergo TENS sessions daily for 10 days for 30 minutes each session ( Gibson et al., 2017). After session completed a structured interview will be conducted, by the primary investigator, to assess for CIPN using the CIPNAT.
Study NCT05237362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Saga Stories
Description: Saga Stories in health talks consists of material for child healthcare nurses to use to facilitate the health talk with both the child and parent(s) and is complemented with take-home material. Every nurse will receive a large flip-chart with colourful pictures and text to facilitate their health talk at the 5-year check-up. The flip-chart will include information and questions regarding food, physical activity and sedentary behaviour, sleep, dental health, as well as bathroom habits. At the conclusion of the check-up the children will receive the book 'Saga Stories: Your amazing body and brain´ as well as games for the child to take home to promote healthy lifestyle behaviours (fruit and vegetable bingo and a physical activity fortune teller).
Study NCT06065332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Velez Intense Hydration Mask® (biotech cellulose face mask)
Description: Application to one randomized side half of a Velez Intense Hydration Mask® (biotech cellulose face mask)
Study NCT04867083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV bitherapie
Description: 1. Dolutégravir 50mg / Lamivudine 300mg per day~2. Dolutégravir 50mg / Rilpivirine 25mg per day~3. Darunavir/r 800mg/100mg / Lamivudine 300mg per day
Study NCT04867083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARV bitherapie
Description: 1. Dolutégravir 50mg / Lamivudine 300mg per day~2. Dolutégravir 50mg / Rilpivirine 25mg per day~3. Darunavir/r 800mg/100mg / Lamivudine 300mg per day
Study NCT05512962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Single suprachoroidal Administration of Triamcinolone acetonide
Study NCT05512962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Semi-automated Suprachoroidal Microcatheter
Description: Ophthalmic Adminstration Device